Q-VLP Platform

Q-VLP Platform

VLPbio patented and propietary technology platform based on Virus Like Particles from Infectious Bursilitis (IBDV). IBDV belongs to the Birnaviridae family and its proteins, in particular VP2, has the ability to genereate viral like structures providing a versatile system for the incorporation of foreign peptides of interest, relevant to human disease in the form of a vaccine.

Peptides of interest are amino acid sequences, other than IBDV sequences, including vaccine components, antigens and epitopes, targeting sequences, pharmacology modulators, inmunostimulators and so, that are relevant to human or veterinary health.

The insertion point for the peptide of interest in the VP2 protein of the IBDV, allows the exposure of  the peptide of interest to the inner or outter part of the mature molecule enabling an inmune or humoral response, even in ausence of adjuvant. 

Technology Overview

  • 1

    Virus Like Particles

    Virus Like Particles (VLP) consist of non-infectious empty viral capsids. These particles resemble the virus from which they were derived but lack viral nucleic acid, meaning that they are not infectious.

  • 1

    Q-VLP Platform

    VLPbio patented and propietary technology platform based on Virus Like Particles derived from Infectious Bursal Disease Virus (IBDV)

  • 1

    Cervivax

    Propietary therapeutic Vaccine against Cervical Intrauterine Neoplastia based on Q-VLP propietary technology.